I think all 3 companies had enough evidence from actual experience selling to indicate it was not realistic to reach their intial goals. Tetraphase made completely wrong assumptions about how much Xerava they would sell pre-launch. But more than a year after launch, it is completely clear that even if they increase revenues by 10x, they will still be bleeding cash.
Also in Industry News
How to decide whether or not to start treatment for prostate cancer?
Analysis of the SARS-CoV-2 proteome via visual tools
$65m investment increases British Patient Capital’s exposure to life sciences and health technology